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Abstract: The questioned reliability of 15:0, 17:0, and trans9-16:1 acids as biomarkers of dairy fat
intake also questions the relationship between the intake of these products and their health effects.
Two studies were conducted in the same geographical region. In an intervention study, volun-
teers followed a diet rich in dairy products followed by a diet without dairy products. Plasma
and erythrocyte fatty acids (FA) were analyzed, and their correlations with dairy product intakes
were tested. The FA biomarkers selected were validated in the Gipuzkoa cohort of the European
Prospective Investigation into Cancer and Nutrition (EPIC) observational study. The correlation
coefficients between plasma concentrations of iso16:0, iso17:0, trans11-18:1, cis9, trans11-18:2, and
cis6-18:1 and the dairy fat ingested are similar in both studies, indicating that their concentration
increases by 0.8 µmol/L per gram of dairy fat ingested. The biomarkers are positively related to
plasma triglycerides (r = 0.324 and 0.204 in the intervention and observational studies, respectively)
and total cholesterol (r = 0.459 and 0.382), but no correlation was found between the biomarkers
and atherogenicity indexes. In conclusion, the sum of the plasma concentration of the selected FAs
can be used as biomarkers of dairy product consumption. A linear relationship exists between their
plasma concentrations and ruminant product intake. These biomarkers allow for obtaining consistent
relationships between dairy intake and plasma biochemical parameters.
Keywords: dairy products; dairy fat; rumenic acid; vaccenic acid; petroselinic acid; iso fatty acids;
biomarkers; plasma; atherogenicity indexes
1. Introduction
Dairy products comprise a group of heterogeneous food products consisting primarily
of milk, cheese, and yogurts from ruminants, mostly cows, sheep, and goats. They provide
a large number of essential nutrients that could be of benefit for most people. However,
their positive effect on human health has been questioned due mainly to their large content
of saturated fatty acids (FA). The review by Thorning et al. [1] concludes that the available
scientific evidence indicates that milk and dairy products contribute to fulfilling nutritional
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recommendations and that they may protect against chronic diseases. On the contrary, other
authors state that, although milk and dairy products have been included in many dietary
guidelines, their association with reduced risk of developing cardiovascular diseases (CVD)
is still controversial [2].
The contradictory results of published research could be due to any or several of the
following reasons: the great variability of the nutritional composition of dairy products,
different dietary patterns and intake of these products in various regions and countries, and
the use of dietary questionnaires to obtain data on intake of dairy products. These methods
are inherently imprecise in calculating the intake of dairy products and the nutrients pro-
vided by the diet. In addition, food composition is highly variable. As a result, coefficients
of variation obtained in epidemiological studies are quite high and the conclusions are not
consistent. For these reasons, it is necessary to define reliable biomarkers to determine as
objectively as possible the intake of dairy products.
More than 400 different FAs have been identified in bovine milk fat [3]. Some of
them are unique because they are synthesized de novo by rumen bacteria. Bacteria in the
rumen synthesize odd-chain FA 15:0 and 17:0, iso or anteiso FA, and trans FA, primarily
vaccenic (trans11-18:1) and rumenic (cis9, trans11-18:2, conjugated linoleic acid (CLA)) acids.
These FAs can reach the mammary gland, where they are incorporated into milk lipids [4].
Thus, in spite of the many different types of dairy products, they have a characteristic
FA composition [3]. In a recent review, Pranger et al. [5] concluded that 14:0, 15:0, 17:0,
and trans9-16:1 (trans-palmitoleic acid) are biomarkers of total dairy and dairy fat intake
commonly used in the scientific literature, the more frequently used ones being 15:0 and
17:0. Nevertheless, their validity was recently questioned [6] because they are found in
foods other than dairy products and because their synthesis by β-oxidation of longer chain
FAs in human tissues was demonstrated [7]. Rumenic acid [8] was also recently proposed
as a dairy intake biomarker.
In most scientific works, molar or weight percentages of fatty acids in plasma or
serum were positively correlated with total dairy intake [5]. Very few studies report the
proportionality relationship between the amount of ingested dairy products and the
absolute concentration of biomarkers in the samples [8,9].
Therefore, we present an intervention study to determine the most appropriate
biomarkers for dairy intake and to calculate the proportionality relationship between
their plasma concentration and the amount of dairy products ingested. The calculated
relationship was then validated in an observational study carried out in the same geo-
graphical region. Subsequently, the correlation between the concentration of biomarkers
and plasma biochemical parameters was analyzed to demonstrate the reliability of the
proposed biomarkers. It was hypothesized that suitable fatty acid biomarkers, present
almost exclusively in ruminant fat and showing a proportional relationship with ingested
dairy fat, will allow for obtaining consistent relationships between dairy intake and plasma
biochemical parameters.
2. Materials and Methods
2.1. Intervention Study
The Ethics Committee of the University of the Basque Country approved the study.
The study was carried out in May and June 2013 in the Basque Country (Spain). All
participants signed the Informed Consent document prior to the start of the study. Subjects
were 10 adult volunteers (8 women and 2 men) of 42.9 ± 11.7 years of age, workers in
the Faculty of the Pharmacy of the University of the Basque Country, with no known
pathologies. At the beginning of the study, subjects answered a validated food frequency
questionnaire [10] to determine their habitual diet. They were asked to follow their habitual
diet, adding at least 375 g of full fat dairy products and recording the amount of dairy
products ingested every day for 18 days. The amount of dairy fat ingested with each type
of food during the first period was calculated from food composition tables [11]. At the
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end of the 18 days and for another 18 days, the subjects were asked to continue with their
habitual diet but with no dairy products.
Blood samples were collected after overnight fasting on day 1, day 18, and the last
day of the study (day 36) in 5 mL vacuum tubes impregnated with EDTA. Plasma and
erythrocytes were separated by centrifugation at 800 g for 30 min. After separation, the
samples were kept frozen at −80 ◦C until analyzed.
2.2. Observational Study
The Gipuzkoa (Basque Country, Spain) European Prospective Investigation into Can-
cer and Nutrition (EPIC) cohort was established between 1992 and 1995 as part of the EPIC
multicenter prospective study [12]. The cohort was comprised of 8417 participants (49.5%
men and 50.5% women with an average 51 and 48 years of age, respectively). Participants
with known pathologies, those with an energy consumption greater than or lower than
3 standard deviations and those that had not fasted for at least 8 h before extracting the
blood sample were excluded for the present study. Individuals were divided into four
identical groups according to dairy intake. Information on usual intake was collected by
the diet history method validated previously [13].
2.3. Fatty Acids Analysis
Methylation and extraction of total FA in plasma and erythrocytes was accomplished in
one step without prior extraction of fat following a modified method of Bondia-Pons [14,15].
Fatty acid methyl esters (FAMEs) were prepared from 200 µL of plasma by sequentially,
adding 2.5 mL of 0.5 M sodium methoxide in methanol followed by 2.5 mL of 14% boron
trifluoride in methanol. The resulting FAMEs were extracted by adding 1.0 mL n-hexane
and were collected in a vial with anhydrous sodium sulphate. For erythrocytes, after
adding sodium methoxide, the cell suspension was sonicated for 3 minutes in 10 s cycles.
FAME separation was achieved by gas chromatography on a 100 m CpSil88 capillary
column (Varian Inc., Mississauga, ON, USA). The chromatograph (Agilent Technologies,
Madrid, Spain) was equipped with an FID detector. FAMEs were identified by comparing
the retention times of the obtained peaks with those of authentic standards. The internal
standard method was used to quantify the amount of each compound, with undecanoic
(11:0), tridecanoic (13:0), and nonadecanoic (19:0) acids as internal standards. The absolute
FA concentration was expressed in µmol/L units.
2.4. Plasma Biochemical Parameters Analysis
In the intervention study, the biochemical parameters (total cholesterol (TC), triglyc-
erides (TG), cholesterol in low density lipoproteins (LDL-C), and cholesterol in high density
lipoproteins (HDL-C)) were determined using commercial enzymatic kits (BioSystems,
Barcelona, Spain) based on the spectrophotometric quantification of quinonimine. Lipopro-
teins were determined by the method of Kelley and Kruski [16].
In the observational study, TC, TG, and HDL-C were determined by enzymatic meth-
ods using an analyzer management system (ARCHITECT 16,000, Abbott diagnostics,
Green Oaks, IL, USA). LDL-C was calculated using the equation of Friedewald [17].
The TC/HDL-C ratio and atherogenic index of plasma (AIP) were calculated, and the
latter was calculated according to the formula AIP = log (TG/HDL-C), with both TG and
HDL-C expressed in molar concentration [18].
2.5. Statistical Analysis
Food intake data were expressed as grams per day (g/day). The FA levels in plasma and
erythrocytes in both studies were expressed in micromole per liter (µmol/L). All analyses were
performed using the IBM-SPSS statistical software, version 25 (IBM, Chicago, IL, USA). The
Shapiro–Wilks test was used to verify the normal distribution of the data of FA concentration
and biochemical parameters. In the intervention study, repeated measures one-way analysis of
variance (ANOVA) was used to compare the averages of FA concentrations and biochemical
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parameters obtained at baseline (day 1) and after completion of both diets (days 18 and 36)
using the Bonferroni test for multiple comparison between days. Pearson correlations were
used to determine the relationships between FA concentrations in the plasma and erythrocytes
for each FA. A principal component analysis (PCA) including the concentrations of all FA and
food intake parameters from dietary questionnaires was performed to identify FA related with
the intake of various foods. A stepwise multiple linear regression analysis (MLRA) was done
to determine the existence of a significant relationship between FA concentrations and dairy
product intake. FA concentrations in plasma and erythrocytes were considered dependent
variables, with the following being considered as independent variables: daily intake of dairy
products or dairy fat (g/day); BMI; daily total energy intake (Kcal/day); and daily intake of
other foods (g/day) such as olive oil, fish, red meat, and biscuits and cakes.
In the observational study, a descriptive statistical analysis and a one-way ANOVA
with a Tukey post hoc test was conducted to determine if there were statistically significant
differences in the FA concentrations and biochemical data among quartiles. PCA and
MLRA were performed using the same factors as described for the intervention study.
To analyze the linear relationships, individuals of the observational study were classified
in deciles, with decile 0 including all cases corresponding to participants who declared
no intake of dairy products. Least square averages of FA concentrations for each decile
adjusted to total energy intake (Kcal/day) were calculated and graphed versus the median
values of dairy products (or dairy fat) intake of each decile.
Partial correlations were analyzed between the biochemical parameter values and
total dairy intake (g/day), dairy fat intake (g/day), and plasma concentration of the sum
of FAs chosen as biomarker adjusted by BMI and total energy intake (Kcal/day). Statistical
significance was declared at p < 0.05.
3. Results
3.1. Intervention Study
Participants in the intervention study (n = 10) were asked to follow their habitual
diet (the baseline characteristics of individuals and their habitual diet are shown in Table
S1). During the intervention, in the period of dairy intake, the minimum amount of
dairy products consumed by each participant was defined considering the intake of these
products in the Spanish population based on a Mediterranean diet [19]. Each participant
was free to choose product(s) and amount(s) of dairy products to consume according to
her/his preferences and eating habits. Table 1 shows the average amount of dairy products
ingested every day and the amount of dairy fat ingested with each type of food, calculated
according to food composition tables [11]. The final amount consumed by participants was
544.3 ± 149.7 g/day (33.1 ± 9.2 g of dairy fat/day), which was higher than their habitual
dairy intake (382.2 ± 123.2 g/day, Table S1) and the normal dairy intake in the region [19].
Table 1. Intake of dairy products and fat from dairy products by participants in the intervention study.
Dairy Product Intake, Mean (SD) 1 Dairy Fat Ingested, g/day 2
Whole milk 266.7 (140.5) mL/day 9.62 (5.23)
Full fat yogurt 182.9 (76.7) g/day 6.33 (2.68)
Fat cheese 55.9 (25.4) g/day 17.3 (8.74)
Others 3 38.9 (25.1) g/day 1.59 (1.46)
Total 544.3 (149.7) g/day 33.1 (9.22)
1 SD: Standard Deviation. 2 Calculated using food composition tables [11]. 3 Other milk products: cheesecake,
curd, milk chocolate, béchamel, cream, ice cream, fresh cheese, and chocolate mousse.
Table 2 shows the concentration (µmol/L) of FAs in the plasma of participants. Com-
paring mean values with no dairy intake (NDD) and dairy-rich diet (DRD), it can be
observed that data from the plasma after DRD are between 333% (petroselinic acid, cis6-
18:1) and 10% (12:0) higher for 17 of the 43 individual FAs identified and quantified in
the plasma. In the same way, the concentration of the sum of even-chain and odd-chain
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saturated FAs and the sum of CLAs are higher in the plasma of participants after the DRD.
Likewise, in erythrocytes (Table S2), significant increases (between 115% (rumenic acid)
and 18% (15:0)) were observed in 21 individual FAs and in the sums of even-chain and odd-
chain saturated FAs, and monounsaturated (cis- and trans-) and polyunsaturated FAs (CLA
included). The concentrations of 10 FAs was significantly higher both in plasma and in
erythrocytes after the DRD. As expected, most of the FA showing increased amounts were
characteristic of dairy products: medium-chain FAs (10:0–14:0), 17:0, branched-chain FAs
(iso and anteiso), vaccenic acid, and CLA (rumenic and trans9, trans11–18:2). To determine
whether changes in FA concentration in plasma correlated with changes in erythrocytes,
Pearson correlations between the concentration of each FA in plasma and erythrocytes
(Table 2) were calculated. Overall, there is a high correlation between both fractions, with
higher correlation values for those FAs showing increased concentrations with dairy intake
(0.741 for 14:0, 0.613 for 17:0, 0.694 for vaccenic acid, and 0.821 for rumenic acid).
Table 2. Fatty acid (FA) concentration means (µmol/L) in the plasma samples from participants before (baseline) and after
the intervention with the diet without dairy products (no dairy) and the diet with dairy products (with dairy), the standard
error of the mean (SEM), and Pearson correlation between plasma and erythrocyte concentrations for each FA.




10:0 27.87 b 26.82 b 32.88 a 0.53 <0.001 0.145
12:0 94.08 b 104.0 b 113.4 a 1.78 <0.001 0.155
14:0 99.83 b 90.08 c 153.1 a 7.15 0.001 0.741 ***
15:0 36.66 a 32.78 b 34.40 a,b 0.68 0.008 0.085
Sum 261.28 b 253.6 b 333.8 a 1.68 <0.001 0.314 ***
LCSFA
16:0 1996 a,b 1868 b 2231 a 107.61 <0.001 0.377 **
17:0 21.02 b 18.61 b 24.53 a 0.70 <0.001 0.613 ***
18:0 692.9 607.0 669.6 19.44 0.150 0.050
20:0 4.79 5.474 5.189 0.15 0.065 0.045
21:0 2.68 2.224 2.614 0.10 0.129 −0.058
22:0 13.86 13.92 17.39 1.41 0.356 0.022
24:0 48.25 42.26 51.82 6.07 0.230 −0.038
26:0 18.95 a 16.39 b 19.03 a 0.49 0.001 0.396 **
Sum 2737 b 2574 b 3021 a 127.30 0.001 0.234 **
ΣSFA 2930 b 2827 b 3355 a 134.16 <0.001 0.240
ΣOCFA 60.36 a 53.61 b 61.59 a 1.19 <0.001 0.146
BCSFA
iso14:0 1.414 1.665 1.655 0.05 0.059 0.108
anteiso14:0 1.993 4.970 3.859 0.95 0.060 −0.024
iso15:0 3.275 b 1.949 c 4.555 a 0.26 <0.001 −0.167
anteiso15:0 1.632 a 0.7894 b 2.278 a 0.13 <0.001 0.192
iso16:0 5.599 b 3.955 c 6.867 a 2.45 <0.001 −0.026
anteiso16:0 0.6568 0.5472 0.4586 0.03 0.068
iso17:0 12.89 a 6.495 b 13.67 a 0.73 <0.001 0.667 ***
anteiso17:0 33.95 33.49 30.84 1.22 0.247 0.345 **
Sum 61.42 56.06 66.98 3.05 0.073 −0.005
c-MUFA
cis9-14:1 23.07 b 15.98 c 28.70 a 1.05 <0.001 0.746 ***
cis9-16:1 129.1 a 103.8 b 128.8 a 12.08 0.004 0.769 ***
cis10-17:1 11.40 10.48 10.65 0.26 0.048 0.179
cis6-18:1 2.353 b 0.9266 c 4.014 a 0.40 <0.001 0.518 ***
cis9-18:1 1768 1788 1932 116.22 0.179 0.469 **
cis11-18:1 132.0 b 145.4 a 131.7 b 4.26 0.019 0.461 **
cis11-20:1 11.41 10.70 10.33 0.58 0.478 0.286 *
cis13-22:1 120.5 88.84 118.8 4.92 0.688 0.521 **
Sum 2197 2182 2374 134.62 0.113 0.464 **
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Table 2. Cont.




trans10-15:1 1.783 a,b 1.496 b 1.703 a 0.05 0.041 0.265 *
trans9-16:1 2.243 1.827 2.256 0.12 0.179 0.178
trans9-18:1 16.78 20.34 17.92 1.13 0.139 0.117
trans11-18:1 5.422 b 3.294 c 7.533 a 0.36 <0.001 0.694 ***
Sum 26.70 26.95 29.41 1.45 0.277 0.303 **
PUFA
trans9,
trans12-18:2 4.615 6.434 4.604 1.01 0.250
cis9, cis12-18:2 3470 3231 3507 110.06 0.161 0.304 *
18:3ω-6 161.1 a 121.4 b 135.0 a,b 6.80 0.003 0.511 ***
18:3ω-3 40.93 a,b 32.53 b 43.44 a 2.32 0.014 0.679 ***
20:4ω-6 945.4 904.9 923.1 25.72 0.420 0.346 **
20:5ω-3 24.81 b 29.15 a 30.42 a 0.69 <0.001 0.646 ***
22:6ω-3 326.1 333.3 339.5 13.68 0.691 0.486 ***




a 4.858 b 13.34 a 0.86 <0.001 0.821 ***
trans10,
cis12-CLA 4.193 6.434 5.933 0.36 0.045 0.034
cis9, cis11-CLA 11.60 8.877 9.93 0.41 0.036 0.338 **
trans9,
trans11-CLA 4.142
a,b 2.886 b 4.228 a 0.25 0.005 0.387 **
Sum 30.70 a,b 23.09 b 33.43 a 1.40 0.001 0.474 ***
TOTAL 10230 a,b 9778 b 10849 a 391.62 0.017 0.221
1 p-value < 0.05 was considered statistical significance. a,b,c letters indicate significant differences in compared groups. 2,* 0.01 < p < 0.05;
** 0.001 < p < 0.01; *** p < 0.001. MCFA, medium chain saturated fatty acids; LCSFA, long chain saturated fatty acids. ΣSFA, sum of saturated
fatty acids; ΣOCSFA sum of odd numbered chain saturated fatty acids; BCFA, branched-chain fatty acids; c-MUFA, cis-monounsaturated
fatty acids; t-MUFA, trans-monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; CLA, conjugated linoleic acids.
The PCA analysis carried out including plasma FA concentrations yielded ten PCs
with eigenvalues higher than 1, explaining 88.05% of the variance. PC1 (32.85% of the total
variance) includes 12 FAs, 11 of which (with loadings close to 0.9) are usually correlated
with dairy consumption, such as 14:0, vaccenic, or rumenic acids. In addition, petroselinic
acid was included in PC1 (loading 0.873). Dairy fat intake was also included in PC1, with
a loading of 0.914. The results for erythrocyte samples were very similar, yielding 11 PCs,
which explained 92.62% of the variance. PC1 explained 35.57% of the variance. Among
the FAs with highest loadings included in PC1 were vaccenic (0.891), rumenic (0.818), 14:0
(0.816), and petroselinic (0.837) acids. PC1 also included dairy fat intake (0.933). Figure 1
shows the plasma (a) and erythrocyte (b) sample scores distributed in the two-dimensional
coordinate system defined by PC1 and PC2. In both cases, PC1 allowed the separation
of samples according to intake, or no intake, of dairy products. In the plasma samples
(Figure 1a), PC2 included cis-monounsaturated FAs (present in the olive oil consumed
in Mediterranean diets) with high weights and it allowed for the separation of samples
(particularly in the dairy-free group) according to olive oil consumption.
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Figure 1. Two-dimensional plots representing the normalized scores for PC1 (x axis) and PC2 (y axis)
obtained for plasma (a) and erythrocyte (b) samples of the intervention study (n = 10): samples after
a diet without dairy products (, ); samples after a diet rich in dairy products (♦, ). Open symbols:
olive oil consumption below 25 g/day; full symbols: olive oil consumption above 25 g/day. The
principal component analyses (PCA) were carried out including plasma or erythrocyte concentrations
of all individual FAs and the intake of dairy fat, olive oil, red meat, fish, and cakes and biscuits. PC1
explained 32.85% and 35.57% of the total variance in plasma and erythrocytes samples, respectively,
and PC2 explained 13.25% and 12.18%, respectively.
A stepwise MLRA was applied including all FAs included in the PC1 as dependent
variables and the following as independent variables: dairy intake (g/day) or dairy fat
intake (g/day), BMI, energy consumption (Kcal/day), and intake (g/day) of foods that
could be confusing factors (red meat, fish, olive oil, and cakes and biscuits). The highest
values of the determination coefficients (R2) were obtained for the relationship between
the concentration (µmol/L) of plasma FA and dairy fat intake (g/day) (Table 3). The
analysis i cluded the intake of o ive oil and cakes and biscuits, eliminating the rest of
the indepen ent vari bles due to their lack of ig ificance (Table 3 and Model 1). The
determination coefficients are slightly lower for the concentration of erythrocyte FAs,
with olive oil as the sole confusing food (Table 3 and Model 2). The coefficients improve
when the analysis is conducted with respect to the sum of the concentrations of some
FAs. Thus, the best determination coefficient in plasma is obtained with the sum of
iso16:0, iso17:0, vaccenic, rumenic, and petroselinic (R2 = 0.871) and in erythrocytes with
the sum of iso17:0, vaccenic, rumenic, and petroselinic acids (R2 = 0.774). The regression
coefficients (B) were determined after subtracting the effect of significant independent
variables (Table 3). B values for plasma and erythrocyte concentration (µmol/L) of the
afore entioned sum of fatty acids and the dairy fat ingested (g/day) are 0.827 and 0.301,
resp ctively (R2 = 0.849 and 0.761). B th the results of the PCA and the high R2 value
ob ained as well as those of the standardize regression coefficients (not hown) indicate
that dairy fat intake is the main factor th t etermines the concentrations of these FA in
plasma and erythrocytes.
3.2. Observational Study
A total of 160 randomized individuals selected from the Gipuzkoa cohort of the
observational EPIC study [12] were divided into four equal groups according to their
consumption of dairy products. Of the 160 participants selected, nine gave extreme values
for at least one of the FAs previously selected as biomarkers of dairy fat intake. The final
number of participants and the dairy intake of each quartile are shown in Table 4. Table S1
summarizes the participant’s baseline anthropometric and diet characteristics. All quartiles
had comparable average values for the variables age, BMI, and total energy intake.
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Table 3. Determination (R2) and regression (B) coefficients between the concentration (µmol/L) of fatty acids in different
types of samples and total dairy fat intake (g/day) from whole milk, full fat yogurt, and fat cheese.
Intervention Study Observational Study (Plasma)
Plasma (Model 1) Erythrocytes (Model 2) Model 3 Model 4
Fatty acid R2 B a R2 b R2 B a R2 c R2 B a R2 B a
14:0 0.849 *** 1.980 0.809 0.787 *** 0.401 0.755
14:1 0.835 *** 0.383 0.802 0.598 *** 0.113 0.581
15:0 0.130 *** 0.141 0.232 *** 0.277
iso15:0 0.495 *** 0.074 0.426
anteiso15:0 0.729 *** 0.044 0.664 0.402 * 0.005 0.134
iso16:0 0.769 *** 0.092 0.737 0.136 *** 0.042 0.259 *** 0.103
17:0 0.697 *** 0.205 0.605 0.423 ** 0.097 0.424 0.140 *** 0.079 0.235 *** 0.242
iso17:0 0.793 *** 0.241 0.743 0.572 *** 0.109 0.530 0.134 *** 0.105 0.262 *** 0.246
trans11-18:1 0.771 *** 0.133 0.735 0.604 *** 0.043 0.593 0.115 *** 0.066 0.261 *** 0.121
cis6-18:1 0.712 *** 0.087 0.679 0.777 *** 0.049 0.777 0.141 ** 0.037
cis9,
trans11-CLA 0.804 *** 0.282 0.780 0.768 *** 0.097 0.752 0.062 ** 0.099 0.201 *** 0.233
Sum d 0.871 *** 0.827 0.849 0.131 *** 0.335 0.260 *** 0.740
Sum e 0.774 *** 0.301 0.761
Model 1: Multiple linear regression (fatty acid concentration (µmol/L) vs. total dairy fat intake (g/day) + olive oil intake (g/day) + cakes
and biscuits intake (g/day)). Model 2: Multiple linear regression (fatty acid concentration in erythrocytes (µmol/L) vs. total dairy fat intake
(g/day) + olive oil intake (g/day)). Model 3: Multiple linear regression (fatty acid concentration (µmol/L) vs. total dairy fat intake (g/day)
+ energy intake (Kcal/day)). Model 4: the same as Model 3 applied to data after resting the meat contribution (see text). a Regression
coefficients for the variable “total dairy fat intake” according to each model. b Determination coefficients from fatty acid concentration vs.
total dairy fat intake residuals graphics according to Model 1. c Determination coefficients from fatty acid concentration vs. total dairy
fat intake residuals graphics according to Model 2. d ∑ trans11-18:1; cis9, trans11-CLA, iso16, iso17, and cis6-18:1. e ∑ trans11-18:1; cis9,
trans11-CLA, iso17, and cis6-18:1. * 0.01 < p < 0.05, ** 0.001 < p < 0.01, *** p < 0.001.
Table 4. Fatty acid concentration means (µmol/L) in plasma samples of participants in the observational study and the
standard error of the mean (SEM).
Dairy Consumption (g/day)
<0.71 9.37–217.74 221.43–351.25 >351.25
Number 35 38 38 40
Plasma fatty acids SEM p 1
15:0 17.92 c 22.53 b 22.61 b 27.08 a 0.63 <0.001
anteiso15 0.8840 b 1.210 a,b 1.191 a,b 1.580 a 0.07 0.012
iso16 7.265 b 8.229 a,b 8.216 a,b 9.087 a 0.26 0.005
iso17:0 17.66 b 22.60 a 23.67 a 23.23 a 0.56 <0.001
trans9-16:1 1.360 b 1.637 b 1.767 a 1.702 a,b 0.05 0.045
cis9-16:1 263.3 a 216.7 a,b 177.0 b 168.2 b 11.87 0.001
17:0 20.28 b 23.08 a,b 22.97 a,b 24.67 a 0.43 0.004
trans11-18:1 6.752 b 9.658 a,b 9.807 a 10.84 a 0.34 <0.001
cis6-18:1 2.050 b 3.318 a,b 3.369 a,b 3.554 a 0.17 0.008
cis9, trans11-CLA 16.82 20.52 20.63 20.50 0.59 0.066
1 p-value < 0.05 was considered statistical significance. Different superscripted a,b,c letters indicate significant differences in compared
groups. CLA, conjugated linoleic acid.
Of the 43 FAs identified in plasma samples, the concentrations of 9 FAs showed
significant differences according to dairy intake (Table 4). Similar to that in the intervention
study, branched-chain, odd-chain, and vaccenic FA concentrations increase as dairy intake
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increases. Moreover, significant differences were obtained for the concentrations of 15:0
and trans-palmitoleic acids but not for the concentration of rumenic acid. In most cases,
significant differences are obtained between the two extreme quartiles, with intermediate
values for quartiles 1 and 2.
The PCA distributed individual FA concentrations among 7 PCs, which explained
77.65% of the total variance. PC1 (32.2% of the variance) included FA related to dairy intake,
with the highest loading for iso17:0 (0.885) and vaccenic acid (0.834). Figure 2 shows the
distribution of the plasma sample’s scores for quartiles 0 and 3 in the coordinate system
defined by PC1 and PC2. Although the sample scores are more dispersed than those in
the intervention study, the samples are distributed along PC1 according to the intake of
dairy products.
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Figure 2. Two-dimensional plot representing the scores for PC1 (x axis) and PC2 (y axis) obtained
for plasma samples of the observational study (n = 151): samples of quartile 0 (low dairy intake, );
samples of quartile 3 (high dairy intake, ♦). The principal component analysis (PCA) was carried out
including plasma concentrations of all individual FAs and the intake of dairy fat, olive oil, red meat,
fish, and cakes and biscuits. PC1 explained 32.2% of the total variance, and PC2 explained 14.1%.
The stepwise MLRA showed that there is a significant correlation between the concen-
tration of FAs and the intake of dairy products (g/day) (Table 3, Model 3, and R2 for the
sum of FA = 0.131, p < 0.001). Of all the independent variables in lud d, only the daily en-
ergy intake showed a significant effect in addition to dairy int ke. he r gressi n coefficient
(B), determined after subtracting the effect of energy intake, of the aforementioned sum of
FA and the dairy fat ingested (g/day) is 0.335 (R2 = 0.131, p < 0.001). Figure 3 shows a linear
relationship between the sum of FA concentrations and the intake of dairy products and
dairy fat. Similar correlations were obtained for all individual FA that showed a significant
increase in their concentrations in the observational study (Table 3).
3.3. Comparative Analysis
Overall, the concentrations of FAs selected as biomarkers are higher in the observa-
tional study than in the intervention study. The sum of concentrations of selected FA in
quartile 0 (participants who declare no intake of dairy products) was 50.35 ± 16.77 µmol/L,
whereas it was 19.56 ± 5.42 µmol/L in the intervention study after the NDD. Comparing
quartile 3 of the observational study with the intervention study after DRD, the concen-
trations are higher in the observational study, in spite of the intake of dairy in quartile 3
(504.5 ± 134.5 g/day) being similar to that of the intervention study (544.3 ± 149.7 g/day).
However, the increase in the concentration with increasing dairy intake in the former study
was less than that in the latter study, as indicated by the B values (0.335 vs. 0.827 µmol sum
FA.day/L.g milk fat).
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Figure 3. Relation between dairy products (a) or dairy fat (b) intake, and the sum of the concentrations of iso16:0, iso17:0,
cis6-18:1, trans11-18:1, and cis9,trans11-CLA in plasma. Intake data were divided in deciles. The 0 decile includes all
data from participants who declared no dairy intake. Fatty acid concentrations are least-squares means of each decile,
adjusted for energy intake (Kcal/day). Bars represent ± SD values. Median values of intake for each decile are entered
as a continuous variable to obtain the P value for the linear trend. p-values were < 0.001 in both cases. CLA, conjugated
linoleic acid.
One remarkable difference in the diet of both studies was the intake of red meat.
In participants in quartile 0, it was over two-fold (87.8 ± 59.1 g red meat/day) that
of participants in the intervention study (34.8 ± 21.8 g/day) (Table S1). Therefore, the
difference in the sum of selected FA concentrations might be due to the differences in
red meat (ruminant-derived almost exclusively) intake. Furthermore, while red meat
in ake does not change during the intervention study, in the bservational study, the intake
of dairy products increases across the quartiles the intake of red meat decreases (from
87.8 ± 59.1 to 47.9 ± 32.2 g/day). Thus, the contribution of red meat to the concentrations
of selected plasma FAs can be different in each quartile. To correct (in an approximate
manner) for the likely contribution of red meat, the ratio “FA concentration/red meat
intake” was calculated for quartil 0, assuming th t, in this quartile, red meat is the only
source of these FAs. The same ratio was calculat d for the selected FA concentrations in
the dairy-free diet in the intervention study. The calculated values are similar (Table S3) in
both studies (0.640 ± 0.360 and 0.718 ± 0.408 for the sum of selected FA in the intervention
and observational studies, respectively).
After subtracting the contribution of red meat from the concentrations of plasma
FA in quartiles 1–3 of th observational study (Table 3 an Model 4), the determination
coefficients improve (0.260 vs. 0.131 for the sum of FA) and regression coefficients (B) for
the selected FAs in the observational study turn out to be similar to those obtained in the
intervention study. Thus, the proportionality relationship between the sum of plasma
concentrations of selected FAs and dairy fat intake is 0.8 µmol.day/L.g, approximately, in
both studies.
3.4. Biochemical Parameters
The plasma lipid parameters for both studies are summarized in Table S4. No statisti-
cally significant (p ≥ 0.05) differences were observed in either study when the mean values
of the parameters were compared among the groups according to their dairy intake, as
declared in the diet questionnaires. Nevertheless, in the analysis of partial correlations
adjusted for BMI and energy intake (Kcal/day), significant correlations were found when
plasma lipid parameters were correlated with the concentrations of the selected biomarkers
(Table 5). In both studies, plasma concentrations of biomarkers are positively correlated
with plasma TG, TC, LDL-C, and HDL-C, but no significant correlation was found with
atherogenic indexes (TC/HDL-C or AIP).
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Table 5. Partial correlations (r) between biochemical serum parameters and dairy for the samples taken in the intervention
study and the observational study.
Biochemical
Parameters
Intervention Study Observational Study
r 1 r 2 r 3 r 1 r 2 r 3
TG, mg/dL 0.089 0.121 0.324 * −0.069 −0.057 0.204 *
TC, mg/dL 0.064 0.189 0.459 ** −0.026 −0.003 0.382 **
LDL-C, mg/dL 0.139 0.203 0.348 * 0.008 0.009 0.328 **
HDL-C, mg/dL −0.091 0.060 0.341 * −0.050 0.004 0.206 *
TC/HDL-C 0.229 0.178 0.110 0.025 −0.019 0.112
AIP 0.247 0.179 0.207 −0.052 −0.045 0.007
1 Partial correlation between biochemical parameter and total dairy intake (g/day) adjusted for energy intake (Kcal/day) and BMI.
2 Partial correlation between biochemical parameter and total dairy fat intake (g/day) adjusted for energy intake (Kcal/day) and BMI.
3 Partial correlation between biochemical parameter and plasma fatty acid concentration (µmol/L of ∑iso16:0, iso17:0, trans11-18:1, cis9,
trans11-CLA, and cis6-18:1) adjusted for energy intake (Kcal/day and BMI. * p < 0.05, ** p < 0.01. TG, triglycerides; TC, total cholesterol;
LDL-C, cholesterol in low density lipoproteins; HDL-C, cholesterol in high density lipoproteins; AIP, Atherogenic Index of Plasma; log
(TG/HDL-C).
4. Discussions
The present investigation compares the results obtained in an intervention study with
data obtained in an observational study carried out in the same geographical region. No
similar studies have been found in the scientific literature.
The overwhelming majority of the large number of published articles describing vari-
ous FA as biomarkers of dairy consumption express FA concentrations as weight or molar
percent. Those data only reflect the relative intake of each FA. Absolute concentrations
yield objective quantitative information, without being influenced by the intake of other
foods that may contain significant amounts of other FA [20].
Dietary intervention with high amounts of dairy products yields characteristic FA
profiles of plasma and erythrocytes, which are substantially different from those of individ-
uals with a low or null dairy intake. In addition, the inclusion of dairy fat increases data
variability, as can be seen in Figures 1 and 2, in accordance with de Oliveira Otto et al. [21],
who found that the addition of daily servings of regular cheese, whole-fat milk, and butter
were associated with SD increases in FA concentrations.
Few intervention studies [22–25] analyzed the effect of consuming controlled amounts
of dairy products in the FA profile of various blood fractions. In the present study, 18 days
are sufficient to observe changes in the plasma FA profile, which are highly correlated with
changes in the erythrocyte FA profile, as previously described [9,24,26,27]. Erythrocytes
constantly exchange FA in their membrane phospholipids with those of plasma phospho-
lipids [27], although their half-life is 28 days. Thus, erythrocyte FAs are no better indicators
of long-term changes than plasma FA, as suggested by other authors [5,26]. In addition,
other authors [28–30] demonstrated that total serum FAs reflect FA intake better than
lipid fractions such as cholesterol esters, phospholipids, or triglycerides. It has also been
demonstrated that, when the diet does not change, plasma FA can be as good biomarkers
of long-term intake as those in adipose tissue [28,31].
Although 15:0 [9,21,32,33] or both 15:0 and 17:0 [25,31,34] are the most used biomarkers
of dairy intake, in the present intervention study, only 17:0 increased significantly. These
differences among studies could be due to the fact that the concentrations of these FA in
dairy products may differ in different countries [9]. In addition, their value as biomarkers
has been recently questioned [6,7]. Some authors [9,34] have proposed trans-palmitoleic
acid as a biomarker, although human tissues can also synthesize it from vaccenic acid [35].
Mayneris-Perxach et al. [36] found a significant correlation (r = 0.288) between dairy intake
and the plasma level of rumenic acid; Zong et al. [37] found a significant correlation
(r = 0.37) between the percent of erythrocyte trans-18:1 isomers and dairy intake; and
Pranger et al. [8] proposed that the percent of rumenic and vaccenic acids in TG and
phospholipids could be used as biomarkers of dairy consumption. In the present work,
branched chain FA iso16:0 and iso17:0 [4], and vaccenic and rumenic FA [3] were proposed
Nutrients 2021, 13, 702 12 of 16
as biomarkers as there is no doubt about their rumen origin. In addition, petroselinic acid
has not been related to dairy products intake although it has been described as intermediate
in the rumen biohydrogenation of 18 carbon polyunsaturated FA [38] and it has been found
in some cheeses [39].
In addition to its unequivocal origin, a biomarker must exhibit a proportionality
relationship that allows for calculating the amount of food consumed through its plasma
concentration. The present study demonstrates that the concentrations of the selected FA,
both in plasma and erythrocytes, increased significantly as the amount of consumed dairy
products increased. Because the absolute concentrations of these FA are quite low, the sum
of their concentrations (Table 3) is proposed as a biomarker. Similarly, Pranger et al. [8]
also proposed the sum of the molar percentages of 15:0, 17:0, vaccenic, and rumenic acids
as biomarkers. Only one study [9] was found that described a proportionality relationship
between ingested dairy products, and plasma and erythrocyte 17:0 and trans-palmitoleic
concentrations. Aslibekyan et al. [40] demonstrated that the weight percentage of 15:0 and
17:0 in adipose tissue increases in a proportional manner as their consumption increases.
The results of the intervention study are comparable to those of the EPIC-Gipuzkoa
cohort [12], within the same geographical region but twenty years apart. Both studies
followed a very similar Mediterranean diet, with high intake of fruits, vegetables, cereals,
legumes, fish, and olive oil and a moderate intake of eggs, meat, and dairy. The main
difference is that the consumption of red meat and meat products is considerably lower
in the intervention study. According to Garcia-Closas et al. [41], in Spain, during the
1990s, consumption of meat products was about 200 g/day, a value that is similar to that
declared by participants in the observational study. In 2011, the consumption of meat and
meat products was 145 g/day and that of red meat was 53.4 g/day [42]. These values
are higher than those declared by participants in the intervention study, coinciding with
the decreasing trend, perhaps due to the warnings relating red meat consumption and an
increased risk of developing cancer [43].
Hjaståker et al. [44] determined the consumption of dairy products in the various
EPIC cohorts. Both the Spanish and the Gipuzkoa cohorts gave values higher than other
European cohorts, with 399 g/day for women and 332 g/day for men. According to Valera-
Moreiras [19], the average habitual consumption of dairy products in Spain is 356 g/day.
Thus, the consumption of dairy products within the population of this geographical
region did not change appreciably in the period of time covered by the present study.
Nebwy et al. [45] also demonstrated that dietary habits within a population change very
little with time.
Although small differences in diet are reflected in plasma concentrations of FA, this
study demonstrates that the concentration of the proposed biomarkers is mainly due to
the sum of the contributions of dairy products and red meat and that the contribution of
both types of food is similar in both studies. Several studies mention the contribution of
these foods to the concentrations of biomarker FA, but no study has been found in which
the contribution of each food is estimated. It has been determined that, for each gram
of daily-consumed dairy fat, the sum of the concentrations of biomarker FA increases by
approximately 0.8 µmol/L. However, the plasma total concentration of these FA depends on
the intake of dairy fat as well as on other foods of ruminant origin. That is to say, the amount
of ingested dairy products cannot be directly inferred from the plasma concentrations of
these FA without knowing the intake of those other foods. In addition, given that habitual
consumption of dairy products and red meat as well as the concentrations of the selected
FA in these foods changes in various countries [9,43,45], it is not possible to extrapolate the
results obtained in the present study to other populations without carrying out the same
analysis. Saadatian-Elahi et al. [46] compared the plasma FA profiles of EPIC participants
from different European regions and demonstrated that the factor “region” determines the
variations observed among the different cohorts, which in turn, depend most likely on the
different dietary habits and life styles in each region.
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Finally, the present work shows that biomarkers yield solid and consistent correlations
between the intake of dairy products and disease risk biomarkers. On the contrary, when
dairy intake is calculated from dietary surveys, the results found in the literature are
contradictory [47]. Thus, the present work shows that biomarker concentration is positively
correlated with an increase in LDL-C and HDL-C but not in TC/HDL-C or AIP. Huth and
Park [48] also concluded that the results of short-term intervention studies with high intake
of full-fat dairy increased LDL-C and HDL-C but did not increase the ratio TC/HDL-C.
The increase in the concentration of biomarkers FA was also correlated with an increase
in plasma TG, although the levels were within the recommended range. These results are
repeated in the two studies, in spite of their different design and the time span between the
two studies, which attests to their validity. Patel et al. [49] also found that FAs measured
in plasma and erythrocytes were more strongly associated with diabetes incidence than
data obtained from food frequency questionnaires, emphasizing the importance of using
objective biomarkers to determine intake.
The major limitation of the present study is the small sample size and the unbalanced
composition of the intervention study. Nevertheless, in our opinion, the results obtained
in the observational study validate the results obtained in the intervention study despite
its limitations.
5. Conclusions
Two studies were carried out in the same geographical region with basic Mediter-
ranean diet over a 20-year interval. The use of plasma concentrations of selected FAs
(iso16:0, iso17:0, vaccenic, rumenic, and petroselinic acids) as biomarkers of dairy intake in
an intervention study was validated in an observational study. The plasma concentration of
the sum of these FAs increases proportionally as the intake of dairy products increases, and
the relationship was stable over time. Dairy products are not the only food source of those
FAs, and therefore, the intake cannot be inferred from their absolute plasma concentrations,
although they can be used in comparative studies within a region, particularly when
the consumption of red meat is known. These biomarkers allow for obtaining coherent
relationships between food intake and plasma biochemical parameters. Dairy fat intake is
positively correlated with an increase in TG, LDL-C, and HDL-C but not with TC/HDL-C
or AIP.
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